iBio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- iBio Inc.
- Former names
- iBioPharma, Inc. InB:Biotechnologies, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- June
- Ticker symbol
- IBIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001420720
- EIN
- 26-2797813
Board of directors
-
Alexandra Kropotova · DirectorSince 2024
-
Antonio Bernardino Guimaraes Parada · DirectorSince 2024
-
David Arkowitz · DirectorSince 2024
-
Elizabeth Stoner · DirectorSince 2026
-
Evert B. Schimmelpennink · DirectorSince 2024
-
Gary Sender · DirectorSince 2024
-
Martin Brenner · Director · See RemarksSince 2025
-
William D. Clark · DirectorSince 2024
Director election results
Annual meeting of November 20, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
59.8%
-
98.5%
Board connections
3 of this board's directors also sit on 6 other boards.
- via William D. Clark
- via Gary Sender
- via Evert B. Schimmelpennink
- via Gary Sender
- via Evert B. Schimmelpennink
- via Gary Sender
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $98,109
- 4 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Banjak Marc Officer (Chief Legal Officer) | Open-market purchase | +12,500 | $1.64 | $20,500 |
| Mar 26, 2026 | Banjak Marc Officer (Chief Legal Officer) | Open-market purchase | +1,434 | $1.76 | $2,524 |
| Mar 19, 2026 | Duran Felipe Officer (Chief Financial Officer) | Open-market purchase | +24,835 | $2.02 | $50,167 |
| Mar 19, 2026 | Martin Brenner Director, Officer (See Remarks) | Open-market purchase | +12,336 | $2.02 | $24,919 |
| Jan 10, 2025 | Duran Felipe Officer (Chief Financial Officer) | Open-market purchase | +9,191 | $2.72 | $25,000 |
| Jan 10, 2025 | Martin Brenner Director, Officer (See Remarks) | Open-market purchase | +9,191 | $2.72 | $25,000 |
| Jan 10, 2025 | Banjak Marc Officer (Chief Legal Officer) | Open-market purchase | +9,191 | $2.72 | $25,000 |
| Jan 10, 2025 | David Arkowitz Director | Open-market purchase | +18,382 | $2.72 | $49,999 |
| Jan 10, 2025 | William D. Clark Director | Open-market purchase | +1,838 | $2.72 | $4,999 |
| Jan 10, 2025 | Antonio Bernardino Guimaraes Parada Director | Open-market purchase | +183,823 | $2.72 | $499,999 |
| Jan 10, 2025 | Gary Sender Director | Open-market purchase | +9,191 | $2.72 | $25,000 |
| Nov 1, 2023 | Martin Brenner Officer (See Remarks) | Open-market sale | −4,881 | $0.27 | $1,318 |
| Oct 3, 2023 | Martin Brenner Officer (See Remarks) | Open-market sale | −5,267 | $0.30 | $1,580 |
| Oct 2, 2023 | Martin Brenner Officer (See Remarks) | Open-market sale | −4,215 | $0.31 | $1,307 |
| Aug 28, 2023 | Martin Brenner Officer (See Remarks) | Open-market sale | −5,011 | $0.31 | $1,553 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.